Cyclophosphamide Articles
US FDA warns on renal, hepatic and gastro problems with Novartis’ Exjade; clears Roche/Biogen’s Rituxan for CLL
19 February 2010
US FDA clears restart of Roche Ph III Avastin trials; other strong data presented at San Antonio meeting
14 December 2009
MabThera for leukemia OKed in Scotland
8 June 2009
Millennium presents Ph I Velcade trial results
15 December 2008
Avastin + Herceptin HER2 study initiated
9 June 2008
Mayo study shows potential of Oncolytics' Reolysin
14 January 2008
Roche's MabThera gets nod for EU label extension
24 December 2007
Avastin shows good safety profile in Ph II breast cancer trial
24 December 2007
Accentia agrees with FDA on Revimmune trial
15 October 2007
Recruitment opens in Ph II Velcade combo MM trial
20 August 2007
CellCept falls short in Phase III trial
9 July 2007
Velcade produces 54% CR rate in MM
9 July 2007
Lilly reports benefits of Alimta in NSCLC
11 June 2007
Combined Reolysin effective in animal cancer models
26 March 2007
Accentia licenses global rights to Revimmune
5 March 2007
YM's Ph III tesmilifene trial to continue
22 January 2007
Herceptin/Taxotere improve DF survival
22 December 2006
Strong data for Sanofi's Taxotere in node (+) breast cancer
22 December 2006
November a lackluster month for biotechnology stocks, says Burrill
18 December 2006
Herceptin gets FDA ok for HER2 node
27 November 2006
UK's NICE OKs Sanofi's Taxotere
2 October 2006
NICE approves MabThera as first-line therapy for NHL
2 October 2006
YM Bio's tesmilifene trial gets IDSMB OK
4 September 2006
Japan to discuss pediatric drug use
10 April 2006
Genentech/Biogen Idec submit Rituxan sBLA
3 April 2006
Strong Ph I/II data for Cell Thera's pixantrone
27 March 2006
Genasense shows benefits in CLL trial
27 February 2006
ZIOPHARM's ZIO-201 may have role in bone marrow transplant
27 February 2006
FDA approves Rituxan for NH lymphoma
20 February 2006
Genta starts NDA for Genasense Injection
11 July 2005
Partnerships needed for LDC pediatric cancers
6 June 2005
Abraxane Ph II trial finishes recruitment
16 May 2005
Taxotere cleared for two new indications
17 January 2005
Roche's MabThera improves survival in NHL at 30 months
20 December 2004
Sanofi-Aventis/Genta stop Genasense deal
15 November 2004
Sopherion raises $47M; buys Myocet rights
4 October 2004
Aventis Taxotere gets OK for new use by FDA
23 August 2004
Pixantrone on FDA fast track for NHL
19 July 2004
MabThera on track for first-line use in NHL
5 July 2004
Positive new data for Roche's CellCept
22 March 2004
MabThera EU filing for first-line indolent NHL
26 January 2004
New data for Rituxan/ MabThera at ASH
15 December 2003
Aventis' Taxotere shows promise in early-stage breast cancer, filings expected 2004
15 December 2003
Rituximab meets goal in NHL trial
24 November 2003
UK NICE recommends Roche's MabThera
29 September 2003
Taxotere boosts survival in breast cancer
27 May 2002
Roche's Xeloda in Ph III as first-line agent
11 March 2002
Mabthera/CHOP increase chance of NHL cure
13 December 2001
Orphan product approvals
6 December 2001
Update: Roche cancer drugs backed by CPMP
24 October 2001
CPMP recommends Roche's MabThera
22 October 2001
Biomira begins Ph II BLP25 trial
22 October 2001
New NICE guidance on Fludara in CLL; breast cancer advice on taxanes to
25 September 2001
Further promising preclinical data for Oncolytics' Reolysin
10 August 2001
Oxford BioMedica's MetXia program oked
11 July 2001
MabThera filed for aggressive NHL in EU
18 May 2001
Inex begins Phase II Onco TCS trial in NHL
27 March 2001
2000, a year of achievement for Oxford BioMedica
30 January 2001
Rituxan combination ups survival in NHL; Zevalin update
6 December 2000
Rituxan combination ups survival in NHL
1 December 2000
Oxford BioMedica sees promise with MetXia
9 November 2000
Elan gains European approval for Myocet
2 August 2000
FDA OKs new regimen for cancer drug Taxol
11 July 2000
Genta rises on NHL preclinical trials
9 June 2000
Europe reaches positive Myocet opinion
17 April 2000
NEJM warns against breast cancer therapy
8 March 2000
Oxford BioMedica leaps on cancer drug
4 February 2000
TLC suffers as FDA requests more data
4 February 2000
R-PR gets FDA panel OK for Taxotere use
15 December 1999
Genentech and IDEC seek to broaden NHL indications for Rituxan
8 December 1999
Liposome Company to resubmit Evacet filing
19 October 1999
Mixed fortunes for companies from latest ODAC deliberations
21 September 1999
Epirubicin cleared in USA for node-positive early breast cancer
21 September 1999
TLC initiates Evacet trial with Herceptin
6 August 1999
B-MS' Taxol improves survival in breast cancer
6 August 1999
TLC files Evacet in Canada
22 July 1999
TLC files for Evacet in EU
2 July 1999
TLC files Evacet for breast cancer in USA
24 February 1999
-Orphan Medical shipsBusulfex across USA
23 February 1999
GLYCODesign gets FDA approval for GD0039 trials
23 February 1999
Orphan's Busulfex approved in USA
10 February 1999
Herceptin Heads Cancer Drugs Backed In USA
10 September 1998
Sanofi's Eloxatin Gearing Up For Global Roll-Out
30 June 1998
SB's Hycamtin Supported For SCLC
4 June 1998
Taxol, Platinum "Optimal" For Ovarian Cancer
27 May 1998
Herceptin Data Live Up To Expectations
20 May 1998
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
